What it is
Owkin applies machine learning to real-world patient data — histopathology slides, genomics and clinical records — using federated learning to train across hospitals without moving sensitive data. It builds pathology foundation models and biomarker/target-discovery tools, and runs its own 'AI biotech' pipeline.
Evidence trail
BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.
Model passport
How Owkin represents biology
Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.
Biological scale
Modalities & tasks
Registry, claims and frontier intelligence
Version history not yet curated
1 version record · release year not yet normalized. Model-family identity remains separate from capability and access changes.
Explore version lineage →0 normalized claims
No task, dataset, split and metric claim has been normalized for this record yet.
Open claim intelligence →0 connected frontiers
No frontier-research record currently connects to this model.
Inspect research horizon →Inputs and outputs
Inputs
Project-specific biological dataOutputs
Models, evidence or candidatesScientific and technical profile
Scientific principles
Technology
Scientific lineage
These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.
Transformer self-attention
Ashish Vaswani and colleaguesProtein, genome, molecule and single-cell foundation models use attention to learn dependencies across biological sequences and multimodal inputs.
Selective toxicity and the ‘magic bullet’
Paul EhrlichTarget selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.
Rational antimetabolite drug design
Gertrude B. Elion & George H. HitchingsMechanism-based design, pathway selectivity and iterative medicinal chemistry are direct descendants of this strategy.
Hybridoma production of monoclonal antibodies
Georges J. F. Köhler & César MilsteinTherapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.
Evaluation evidence
BioAtlas has not yet extracted a structured benchmark claim for this record.
Known limitations
- Performance depends on the evaluation dataset and operating conditions.
- A structured benchmark claim has not yet been extracted for this record.
- Outputs require task-specific scientific and experimental validation.
Milestones
Pioneered federated learning across hospital networks.
Released open pathology foundation models.